Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals.Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.Preceding his corporate executive roles, Andrew has served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio. Andrew was also the Head of Asia Pacific Technology Research for J.P. Morgan Securities and General Manager for J.P. Morgan Securities Taiwan.Before his sell-side and buy-side posts, Mr. Lin worked for management consulting firms, McKinsey & Company and Booz • Allen & Hamilton, in both Asia Pacific and the United States.Prior to his management consulting career, Mr. Lin worked for AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation in the United States in a research and development capacity.Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.